Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients

Cited by (355)

Items 201–300 of 355

1. Low apolipoprotein B and LDL-cholesterol are associated with the risk of cardiovascular and all-cause mortality: a prospective cohort
   Xiaolin Yu, Yujuan Yuan, Xiangyu Dong, Zulipiyemu Xier, Ling Ma, Hui Peng, Guoqing Li, Yi‐Ning Yang · 2025 · Annals of Medicine
2. Lipoprotein(a) Cholesterol Masquerading as Low-Density Lipoprotein Cholesterol
   Guillaume Paré, Michael Chong, Pedrum Mohammadi‐Shemirani · 2022 · Journal of the American College of Cardiology
3. Non-HDL Cholesterol May Be Preferred over Apolipoprotein B-100 for Risk Assessment when Evaluated by Receiver Operator Characteristic Curve Analysis
   Stanley S. Levinson · 2024 · The Journal of Applied Laboratory Medicine
4. Lipid profiles and their association with incident carotid atherosclerosis: A community-based prospective study in Taiwan
   Tzu‐Wei Wu, Chao‐Liang Chou, Chun-Chieh Liu, Chuen-Fei Chen, Chun-Fang Cheng, Liyu Wang · 2025 · Nutrition Metabolism and Cardiovascular Diseases
5. Initiating Preventive Care for Hyperlipidemia in the Emergency Department: The Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
   Nicklaus P. Ashburn, Anna C. Snavely, Molly R Ehrig, Michael David Shapiro, David M. Herrington, David M. Reboussin, Sabina B. Gesell, Simon A. Mahler · 2025 · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine
6. Relationship between dynamic changes in remnant cholesterol and cardiovascular disease in middle-aged and older Chinese: a national cohort study
   Bin Zhang, Dengfeng Ma, Zhiqiang Pei, Qian Ren, Jin Feng Qiu · 2025 · Frontiers in Cardiovascular Medicine
7. Non-high-density lipoprotein cholesterol/high-density lipoprotein cholesterol is a predictor for cardiovascular mortality in patients with diabetes mellitus
   Deng Pan, Pengfei Chen, Si-Yan Ji, Tielong Chen, He Zhang · 2025 · World Journal of Cardiology
8. Assessing coronary artery disease severity using the TyG index in patients with LDL-C < 2.6 mmol/l
   Jiao Li, Wenjun Jia, Ya‐Fang Chen, Yue Liu, Linlin Fang, Xin Qi, Liping Wei · 2025 · Lipids in Health and Disease
9. Impact of remnant cholesterol on cardiovascular outcomes in non-myocardial infarction patients undergoing percutaneous coronary intervention
   Nicholas L. Pitaro, Benjamin Bay, Samantha Sartori, Birgit Vogel, Mauro Gitto, Kenneth F. Smith, Yihan Feng, Francesca Maria Di Muro, Angelo Oliva, Johny Nicolas et al. · 2025 · European Journal of Preventive Cardiology
10. Low-density lipoprotein quantity versus quality: Discordance between equation-based low-density lipoprotein cholesterol estimations and oxidized low-density lipoprotein as a determinant of residual cardiovascular risk in coronary artery disease
    Gobardhan Kathariya, Jyoti Aggarwal, Rajesh Nandal, Sreenivas Reddy · 2025 · Heart India
11. Moving Beyond LDL-C and Non-HDL-C: Apolipoprotein B as the Stronger Lipid-Related Predictor of Coronary Artery Disease in Statin-Treated Patients
    Alexandru Raul Jigoranu, Ovidiu Mitu, Alexandru Dan Costache, Alexandru Florinel Oancea, Radu-Ştefan Miftode, Ana Maria Buburuz, Amin Bazyani, Paul Simion, Radu Sebastian Gavril, Petru Cianga et al. · 2025 · Diagnostics
12. Pravastatin-Loaded nanostructured lipid carriers: formulation optimization and in-vivo assessment for antihyperlipidaemic effect in rats
    Anjali More, Ameeduzzafar Zafar, Omar Awad Alsaidan, Misbahuddin M. Rafeeq, Ali Hazazi, Abdulkarim S. Binshaya, Jawaher Amer Alsaiari, Shoaeb Mohammad Syed · 2026 · Journal of drug targeting
13. Diagnosis of Familial Hypercholesterolemia in Children: From Clinical Features Through Gene Variants to Polygenic Score
    Raffaele Buganza, Cecilia Nobili, Giulia Massini, Giovanna Cardiero, Maria Donata Di Taranto, Luisa DE SANCTIS, Ornella Guardamagna · 2026 · Genes
14. LL-37–ApoB-100 Complex Serves as a Biomarker of Coronary Artery Disease
    Yaqun Fang, Zhiye Zhang, Qiqi Cao, Ya Li, Yong Duan, 平嶋 邦猛, Zilei Duan, Wang Gan, Jinai Gao, Muxing Hua et al. · 2026 · Arteriosclerosis Thrombosis and Vascular Biology
15. Are we underestimating the benefits of lipid-lowering therapies?
    Angela Pirillo, Manuela Casula, Elena Olmastroni, Stefano Scotti, Alberto Corsini, Alberico Luigi Catapano · 2026 · Pharmacological Reviews
16. Lipid clinics worldwide: harmonization and guidance on how to optimally organize and fund. European Atherosclerosis Society consensus statement across 55 countries and more than 500 lipid clinics
    Christian Bork, Børge Grønne Nordestgaard, Berit Storgaard Hedegaard, Michal Vrablik, Elsie Evans, Tomáš Freiberger, Zlatko Fras, David Nanchen, Fouzia Sadiq, Kausik Kumar Ray et al. · 2026 · Atherosclerosis
17. Apolipoprotein B: An essential cholesterol metric for atherosclerotic cardiovascular disease
    Kyle Fischer, Layla Kassem · 2022 · American Journal of Health-System Pharmacy
18. Evaluation of cardiopreventive effects of Ximenia americana (Linn.) and Pappea capensis (Eckl. and Zeyh.) leaf aqueous extracts in rat models with myocardial infarction
    Daniel Muthee Gaichu, Patricia M. K. Mathabe, Mathew Piero Ngugi · 2023 · Future Journal of Pharmaceutical Sciences
19. Comparison of creatine kinase-MB, troponin-I, troponin-T, Triiodothyronine, Thyroxine, Apoprotein-B and homocysteine between non-smokers, smokers at high altitudes, and smokers at sea level
    Gaffar Sarwar Zaman, Mushtaq Ahmad Mir, Nasreena Bashir, Venkata Nagaraj Kakaraparthi, Forhad Akhtar Zaman · 2023 · Cellular and Molecular Biology
20. Predictive role of monocyte count for significant coronary artery disease identification in patients with stable coronary artery disease
    Tomasz Kamil Urbanowicz, Anna Olasińska‐Wiśniewska, Michał Michalak, Anna Komosa, Krzysztof Jerzy Filipiak, Paweł Uruski, Artur Radziemski, Andrzej Tykarski, Marek Jemielity · 2023 · Cardiology Journal
21. Apolipoprotein B and Lipid Profile in Italian Children and Adolescents
    Francesco Martino, Tarcisio Niglio, Eliana Martino, Vincenzo Paravati, Luisa DE SANCTIS, Ornella Guardamagna · 2024 · Journal of Cardiovascular Development and Disease
22. Effective exosomes reduction in hypercholesterinemic patients suffering from cardiovascular diseases by lipoprotein apheresis: Exosomes apheresis
    Sophie Schröder, Robert Epple, André Fischer, Volker J. J. Schettler · 2024 · Therapeutic Apheresis and Dialysis
23. Impact of risk factors on intervened and non-intervened coronary lesions
    Xincheng Sheng · 2024 · American Journal of Cardiovascular Disease
24. Validation of the role of apolipoproteins in coronary artery disease patients with impaired kidney function for prognosis: a prospective cohort study in China
    Zixiang Ye, Enmin Xie, Zhangyu Lin, Chenxi Song, Rui Zhang, Haoyu Wang, Yongbao Zhang, Kefei Dou · 2025 · Nutrition Journal
25. Non-high-density lipoprotein cholesterol outperforms low-density lipoprotein cholesterol in predicting cardiovascular events among high-risk Asians
    Worapaka Manosroi, Phichayut Phinyo, Mattabhorn Phimphilai, Pisit Hutayanon, Siriluck Gunaparn, Arintaya Phrommintikul, Wanwarang Wongcharoen · 2025 · Journal of clinical lipidology
26. Integration of apolipoprotein B into the SCORE2 framework: implications for cardiovascular risk prediction
    Wen Kai Wong, Fumihiko Takeuchi, Lê Thị Phương Thảo, Stephen James Nicholls, Derek P. Chew, Karlheinz Peter · 2025 · European Journal of Preventive Cardiology
27. High Cumulative Non-High-Density Lipoprotein-Cholesterol Concentration Increases the Risk of New-Onset Arterial Stiffness ― A Prospective Cohort Study ―
    Guanzhi Chen, Yanjuan Chen, Yan Yao, Ligang Ding, Shouling Wu, Weiqiang Wu · 2025 · Circulation Journal
28. Clinical reasoning and prevention of cardiovascular disease
    Allan D. Sniderman, Michael J. Pencina, George Thanassoulis · 2021 · Journal of clinical lipidology
29. Effect of in-hospital evolocumab therapy on lipoprotein(a) in patients with acute myocardial infarction: a retrospective cohort study and a propensity score matching analysis
    Ge Gao, Tao Zheng, Beidi Lan, Weiying Hui, Shi Chen, Zuyi Yuan, Yue Wu, John Y.L. Chiang, Tao Chen · 2023 · Cardiology Plus
30. Selección de lo mejor del año 2021 en riesgo vascular y rehabilitación cardiaca
    Raquel Campuzano Ruíz, Vicente Arrarte, Rosa Fernández Olmo, Almudena Castro Conde, Pilar Mazón‐Ramos, Araceli Boraíta Pérez, Patricia Palau, Miriam Sandín Rollán · 2021 · REC CardioClinics
31. Changing Recommendations on the Use of Non-Fasting Versus a Fasting Lipid Profile: A Review of Current Literature
    Kaumudi Bery, Muhamad Ali Alherk, Mohammad Ammar Mohamad Kais Yahia, Kiran Govindankutty · 2022 · Scholars Journal of Applied Medical Sciences
32. Triglycerides, Triglyceride-Rich Lipoproteins, and High-Density Lipoprotein in Coronary Heart Disease Risk Assessment
    Anne Tybjærg‐Hansen, Børge Grønne Nordestgaard · 2023 · Elsevier eBooks
33. A novel fully human anti‐NT‐ANGPTL3 antibody from phage display library exhibits potent ApoB , TG, and LDL‐C lowering activities in hyperlipidemia mice
    Panpan Zhang, Ke Wang, Tuo Hu, Menglong Xu, Xiangyan You, Manman Chen, Xuan L. Tang, Huajing Hu, Yiwei Jiang, Wenfeng Zhao et al. · 2024 · The FASEB Journal
34. Heterogeneity of Apolipoprotein B Levels Among Hispanic or Latino Individuals Residing in the US
    Leandro N. Slipczuk, Toshiki Kuno, Santica M. Marcovina, Katrina R. Swett, Kate K. Orroth, J. Antonio G. López, Shia T. Kent, John N. Booth, Robert C. Kaplan, Daniela Sotres‐Alvarez et al. · 2025 · JAMA Cardiology
35. Inadequate awareness and attention to non-HDL cholesterol: undertreatment of high-risk patients in cardiology practice in Turkey
    Gurbet Özge Mert, Kadir Uğur Mert, Özcan Başaran, Volkan Doğan, İbrahim Rencüzoğulları, Bülent Özlek, Göksel Çinier, Eda Özlek, Murat Biteker, Meral Kayıkçıoğlu et al. · 2025 · Coronary Artery Disease
36. Association between rheumatoid arthritis and blood lipid levels: An integrated epidemiological observational analysis and Mendelian randomization study
    Junlin Yi, Qianhua Li, Rongpeng Gong, Jieli Qin, Xinqun Hu · 2025 · Journal of clinical lipidology
37. Contrasting associations of blood lipids with risk of myocardial infarction in Chinese and European adults
    Wang Hanyu, Robert Clarke, Christiana Kartsonaki, Iona Y. Millwood, Robin Walters, Michael Hill, Daniel Avery, Canqing Yu, DianJian-Yi Sun, Jun Lv et al. · 2025 · European Heart Journal Open
38. Efficacy and safety of ongericimab in patients with dyslipidemia: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials
    Misbah Uddin, Asim Shah, Mohamed Fawzi Hemida, Muhammad Jibran Afridi, Zaryab Bacha, Hammad Iftikhar, Suleman Khan, Hammad Saif, Asad Jamal, Aamer Syed et al. · 2025 · Journal of clinical lipidology
39. Association Between Lipid-Lowering Therapy and Differences in the Distribution of LDL-C, apoB and non-HDL-C
    Marcin Ziółkowski, Karolina Obońska, Jakub Marcin Ratajczak, Piotr Adamski, Maciej Banach, Krzysztof Chlebus, Klaudyna Grzelakowska, Piotr Jankowski, Magdalena Krintus, Jacek Kryś et al. · 2025 · Journal of Clinical Medicine
40. Longitudinal exposure to non‐ HDL ‐C and cardiovascular events, all‐cause mortality in type 2 diabetes: A post hoc analysis of the ACCORD trial
    Yueyue Wang, Xi Meng, Xiaoyun Zhang, Mian Li, Tiange Wang, Zhiyun Zhao, Jieli Lu, Min Xu, Jie Zheng, Weiqing Wang et al. · 2026 · Diabetes Obesity and Metabolism
41. Non–HDL cholesterol and remnant cholesterol are better indicators of atherosclerotic cardiovascular disease risk than LDL cholesterol in patients with chronic kidney disease
    Man Li, Wan‐Jie Gu, Liu-Liu Cao, Shuohua Chen, Xiangjie Duan, Yu-Hao Xu, Shou-Ling Wu, Hai-Yan Yin · 2026 · Atherosclerosis
42. Risk-weighted apolipoprotein B: is it worth the weight?
    Robert Alexander Hegele · 2026 · European Heart Journal
43. Excess apolipoprotein B predicts long-term survival in statin-treated CAD irrespective of achieved LDL-C levels: a pooled cohort analysis
    Wei Pan, Xiaozhao Lu, Ziwei Zhou, Jin Liu, Shaozhao Zhang, Haozhang Huang, Yibo He, Jingru Deng, Yihang Ling, Xianlin Ruan et al. · 2026 · Lipids in Health and Disease
44. Integrating frailty and cumulative lipid burden for stroke risk stratification: a machine learning–guided Athero-Frailty Score from the CHARLS cohort
    Ju‐Shan Sun, Daikang Xu, Guangyu Du, Tongyu Jia, X D Han, Yi Yu, Jianpeng Wang, Zhiyong Yan, Shifang Li, Chao Wang et al. · 2026 · Lipids in Health and Disease
45. Importance and Management of Non–High-Density Lipoprotein Cholesterol in Dyslipidemia Treatment
    Richard Charles O’Brien, Lourdes Ella G. Santos, Brian Tomlinson, Zanariah Binti Hussein, Soo Lim, Hapizah Mohd Nawawi, Hean Yee Ong, SILKI Silki, Sidartawan Soegondo, Ta‐Chen Su et al. · 2026 · JACC Asia
46. Primary Prevention of Dyslipidemia: 10 Practice-Changing Takeaways from the 2026 ACC/AHA Multisociety Guideline
    Dmitry Abramov, Abdul Mannan Khan Minhas, Michael David Shapiro, Vera Bittner, LaPrincess C. Brewer, Eugenia Gianos, Samia Mora, Laxmi S. Mehta, Anandita Kulkarni, Dinesh Kumar Kalra et al. · 2026 · Current Atherosclerosis Reports
47. First count the particles: ApoB, the LDL-C/TC ratio, and the hierarchy of lipid risk assessment
    Natalie Arnold, Wolfgang Köenig · 2026 · European Journal of Preventive Cardiology
48. Lipid Profile Testing and Interpretation
    Danh Q. Nguyen, Zahid Ahmad, Ann Marie Návar · 2026 · Circulation
49. Apolipoprotein B-low-density lipoprotein cholesterol discordance refines cardiovascular risk stratification across metabolic phenotypes
    Jee Ah Kim, Min-Seung Park, Eun Hye Cho, Hee‐Yeon Woo, Hyosoon Park, Min‐Jung Kwon · 2026 · Journal of clinical lipidology
50. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial
    Klara R Klein, CAROL H. WYSHAM, Katherine R Tuttle, Melanie Jane Davies, David Cox, Jiaxun Chen, Wen-Shuo Wu, Max Denning, Rong Liu, Lisa Ludwig et al. · 2026 · The Lancet
51. Relationship between Lipoprotein(a) and Dyslipidemia in the Elderly over 60 Years
    Yo-Han Seo, Hee‐Young Shin · 2022 · Korean Journal of Clinical Laboratory Science
52. Homocysteine in CAD patients-Does it matter?
    K Sowndarya, Arpit Jain, Ramya Shenoy, Padmanabh K. Kamath, Anupama Hegde · 2022 · Biomedicine
53. Glycoprotein and Lipoprotein Profiles Assessed by 1H-NMR and Its Relation to Ascending Aortic Dilatation in Bicuspid Aortic Valve Disease
    Borja Antequera-González, Marta Faiges, Neus Martínez-Micaelo, Laura Galián-Gay, Carmen Ligero, María Ferré Vallverdú, L. Masana, Núria Amigó, Arturo Evangelista, Josep Maria Alegret · 2022 · Journal of Clinical Medicine
54. The ABCB1 C3435T Polymorphism is Associated with Triglyceride Reduction in Atorvastatin-treated Uygur Patients with Coronary Heart Disease and Dyslipidemia: An Observational Study
    Hongjian Li, Lu‐hai Yu, Ting-ting Wang, Jianhua Wu, Tingting Liu, Li Xu, Jie Feng, Huilan Zhang, Hao Shen, Li Sun · 2023 · Endocrine Metabolic & Immune Disorders - Drug Targets
55. Modern prospects of targeted hypolipidemic therapy
    Alexey N. Kuchmin, Нагорный Михаил Борисович, Anatoly M. Grachev, Елена Витальевна Смирнова · 2023 · Bulletin of the Russian Military Medical Academy
56. The importance of the APOB gene expression as a marker in assessing the severity of atherosclerosis in coronary vessels
    Jacek Owczarek, Mariola Rychlik‐Sych, Małgorzata Barańska, Michał Dudarewicz · 2023 · Polskie Archiwum Medycyny Wewnętrznej
57. Association of apolipoprotein B with all-cause and cardiovascular mortality among adults: Results from the National Health and Nutrition Examination Surveys
    Mengqi Yan, Yu Huang, Xiaocong Liu, Chaolei Chen, Dan Zhou, Yuqing Huang, Yingqing Feng · 2023 · The American Journal of the Medical Sciences
58. The Influence of Non-High-Density Lipoprotein Cholesterol on the Efficacy of Genotype-Guided Dual Antiplatelet Therapy in Preventing Stroke Recurrence
    Qin Xu, Xia Meng, Hao Li, Xuewei Xie, Jing Jing, Jinxi Lin, Yong Jiang, Yilong Wang, Xingquan Zhao, Zixiao Li et al. · 2024 · Journal of Stroke
59. Association between cytomegalovirus infection and dyslipidemia in US: an NHANES analysis
    Yiyang Xin, Yun Zhou · 2024 · European Journal of Clinical Microbiology & Infectious Diseases
60. Prognostic Significance of Hypertriglyceridemia in Patients at High and Very High Cardiovascular Risk Depending on the Concentration of Highsensitivity C-reactive Protein
    V. V. Genkel, А. С. Кузнецова, Lubov Pykhova, К. В. Никушкина, A. Yu. Savochkina, Ilya I. Dolgushin, Шапошник Игорь Иосифович · 2022 · Endocrine Metabolic & Immune Disorders - Drug Targets
61. Integrating Advanced Lipid Testing and Biomarkers in Assessment and Treatment
    Alexandra Vaio Sykes, Neeja Patel, Danielle Hyunsook Lee, Pam R. Taub · 2022 · Current Cardiology Reports
62. Reporting LDL cholesterol results by clinical biochemistry laboratories in Czechia and Slovakia to improve the detection rate of familial hypercholesterolemia
    Michal Vrablı́k, Veronika Šálková, Marek Vecka, Vladimír Soška, Marek Budina, Tomáš Šálek · 2023 · Biochemia Medica
63. The AACE 2022 Guideline: An Academic Appraisal
    Saptarshi Bhattacharya, Sanjay Kalra · 2023 · touchREVIEWS in Endocrinology
64. Selección de lo mejor del año 2018 en riesgo vascular y rehabilitación cardiaca
    Pablo Toledo Frías, Raquel Campuzano Ruíz, José Antonio Alarcón Duque, Alejandro Berenguel Senén, María Rosa Fernández Olmo, Manuel Abeytua Jiménez · 2019 · REC CardioClinics
65. Risikostratifizierung: ApoB und Non-HDL besser als LDL
    Frank Lichert · 2021 · Aktuelle Kardiologie
66. Neue Therapieansätze in der LDL-Cholesterin-Absenkung?
    Volker J. J. Schettler · 2021 · Dialyse aktuell
67. U-shaped Association Between Apolipoprotein B and All-Cause Mortality: Results from the National Health and Nutrition Examination Surveys
    Mengqi Yan, Xiaocong Liu, Yuqing Huang, Yu‐Ling Yu, Dan Zhou, Yingqing Feng · 2021 · Research Square
68. Novel Protein-Truncating Variant in the APOB Gene Protects from Coronary Artery Disease: Results from a Pilot-Analysis of Targeted Next-Generation Sequencing of Genes Regulating Cholesterol Homeostasis within a Cardiovascular Cohort
    Gabriele Mango, Nicola Osti, Silvia Udali, Anna Vareschi, Giovanni Malerba, Alejandro Giorgetti, Francesca Pizzolo, Simonetta Friso, Domenico Girelli, Oliviero Olivieri et al. · 2022 · SSRN Electronic Journal
69. Study on the Relationship between Serum Uric Acid Level and Apolipoprotein B in Male Patients with Gout
    洁 李 · 2021 · Advances in Clinical Medicine
70. Research Progress on Gout, Apolipoprotein B and Cardiovascular Diseases
    洁 李 · 2021 · Advances in Clinical Medicine
71. Diabetes mellitus 2022 – Was ist neu?
    Werner Alfons Scherbaum · 2022 · Die Diabetologie
72. Discordance of Circulating Non-HDL Cholesterol with LDL Cholesterol Concerning Long-Term Prognosis in Statin-Treated Individuals with Acute Coronary Syndrome and Previous Coronary Artery Bypass Grafting Undergoing Percutaneous Coronary Intervention
    Chuang Li, Kuizheng He, Yixing Yang, Kuibao Li, Mulei Chen, Lefeng Wang, Yuanfeng Gao, Xiaorong Xu · 2023 · Reviews in Cardiovascular Medicine
73. Late metabolic consequences of childhood cancer
    Vincent G. Pluimakers · 2023
74. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and residual risk
    Ángel Alberto García-Peña, Luz Clemencia Zárate-Correa, Claudia Monsalve · 2023 · Revista Colombiana de Cardiología
75. Lipidomics: A comprehensive view of the lipid profile and its relationship to cardiovascular risk
    Karen Lindo, Álvaro Sebastián Ron Mora · 2024 · Salud Ciencia y Tecnología
76. Effects of Atorvastatin on Carotid Artery Plaques and Blood Lipids in Stroke Patients with Different ApoE Genotypes
    Qi Zhao, Yandong Li, Xiyan Ding · 2024 · International Journal of Pharmacology
77. The Association Between apolipoprotein B and Risk of Cardiovascular Disease：Mendelian randomization analysis
    Pengli Chen, Ziwei Song, Dewang Ran, Lili Li · 2024 · Research Square
78. An Overview of the Guideline Development Process for Atherosclerotic Cardiovascular Disease Risk Reduction with an Emphasis on Guidelines for Cholesterol and Dyslipidemia Management
    Carl E. Orringer · 2024 · Contemporary cardiology
79. Empfehlungen zum Lipidmanagement
    Expertenkonsens, verfasst von Prof. E. Giannitsis für die Konsensusgruppe Lipidakademie Baden-Württemberg · 2024 · Aktuelle Kardiologie
80. Atherogenic lipoproteins particle size and number are more critical determinant of cardiovascular risk than mass of cholesterol present within these – An overview
    Avijit Saha · 2024 · Asian Journal of Medical Sciences
81. Further Reading
    Anatol Kontush · 2024
82. Inclisiran: a systematic review exploring the revolutionary approach of twice-yearly dosing regimen in the treatment of hypercholesterolemia
    Singareddy, Sanjana, Dhakal, Surakchhya, Limbaña, Therese Anne, Murugan, Vignesh, Nazmin, Farhana, Garcia, Jian, Khan, Safeera · 2024 · Cureus
83. NLA Expert Clinical Consensus on apolipoprotein B recommends expanded clinical use and improved patient access
    Kevin Carl Maki, Paul Barton Duell · 2024 · Journal of clinical lipidology
84. ApoB and prognosis of patients with chronic coronary syndrome
    Alberto Cordero, Rosa Fernández Olmo · 2024 · Revista Española de Cardiología (English Edition)
85. Asociación en J entre la apolipoproteína B y resultados CV en pacientes con síndrome coronario crónico tratados con estatinas
    Jining He, Zhangyu Lin, Chenxi Song, Sheng Yuan, Xiaohui Bian, Bowen Li, Wenjun Ma, Kefei Dou · 2024 · Revista Española de Cardiología
86. ApoB y pronóstico de los pacientes con síndrome coronario crónico
    Alberto Cordero, Rosa Fernández Olmo · 2024 · Revista Española de Cardiología
87. Exome Sequencing Identified Susceptible Genes for High Residual Risks in Early‐Onset Coronary Atherosclerotic Disease
    Runda Wu, Ya Su, Jianquan Liao, Juan Shen, Yuanji Ma, Wei Gao, Zheng Dong, Yuxiang Dai, Yao Kang, Junbo Ge · 2024 · Clinical Cardiology
88. Concordance & discordance analysis between LDLc and apolipoprotein B/Non HDLc among statin treated patients
    Avijit Saha · 2024 · Panacea Journal of Medical Sciences
89. Association of non-HDL-C and risk of incident hypertension
    Xinxin He, Lei Yin, Yujie Zhao, Bin Yang, Yang William Zhao, Xueru Fu, Yuying Wu, Mengdi Wang, Mengna Liu, Yijia Su et al. · 2025 · medRxiv
90. A comprehensive study on the underlying mechanisms of the lipid-lowering effects of Bao Li Er Capsule in hyperlipidemia
    Xuelan Fu, Jiehong Xing, Chengjun Yuan, Qingling Liu, Ji-Xiao Zhu, Jinxiang Zeng, Haisha Lu, Huiqing Li, Guoyue Zhong, Jian Liang · 2025 · Journal of Traditional and Complementary Medicine
91. In comparison to LDL, does Apoprotein B improve cardiovascular risk prediction?
    Jennifer Weakley, Courtney Acker, Katie Kelly, Ria Sandhu · 2025 · Evidence-Based Practice
92. Traditional Chinese medicine constitution types and apolipoprotein B in hyperuricemia: Associations with cardiovascular risk
    Shuo Yang, Jinfeng Li, Hongli Zeng, Xueping Zhang, Deliang Xiong, Wenyi Tang, Bin Sun, Peng Yu, Xiaohong He, Weizheng Zhang · 2025 · Journal of Medical Biochemistry
93. Bedre risikoprediksjon med ApoB eller non-HDL-kolesterol
    Tine‐Lise Kalleklev, Anne Cecilie K. Larstorp, Kjetil Retterstøl · 2025 · Tidsskrift for Den norske legeforening
94. Targets Beyond LDL in ASCVD Prevention
    A.N. Patnaik · 2025 · Indian Journal of Clinical Cardiology
95. Correlation analysis of ApoB and TyG index levels with residual cardiovascular risk in patients with acute myocardial infarction
    Yuanyuan Wang, Dachuan Guo, Youzhi Wang, Jianmin Yang, Peng Li · 2025 · Frontiers in Endocrinology
96. Life’s Essential 8 and Mortality Risk in Cardiovascular Disease: Results From a Nationwide Population Survey
    Yang Zhang, Zhiwei Xu, Lin Li, Xiaoya Hong, Hui Xia · 2025 · International Journal of Clinical Practice
97. Serum lipid levels predict mortality of aged patients in acute intracerebral hemorrhage
    J Y Huang, Yong-Bo Ma, Shuqiang Zhang, Chao-Yi Huang, Rui Feng, Wen‐Song Yang · 2025 · Research Square
98. Age-stratified optimal non-HDL cholesterol and all-cause mortality in a healthy Taiwanese population considering personal risk factors
    Edy Kornelius, Tsuey‐Hwa Hu, Chih‐Hua Chiao, Jing‐Shiang Hwang, Ta‐Chien Chan · 2025 · International Journal of Cardiology Cardiovascular Risk and Prevention
99. Additional file 1 of The chain-mediating effect of Crp, BMI on the relationship between dietary intake of live microbes and hyperlipidaemia
    Chen, Jingyi, Fang, Shuhua, Jinlin Huo, Nian Yang · 2024 · Figshare
100. Additional file 2 of Apolipoprotein B is associated with CT-angiographic progression beyond low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in patients with coronary artery disease
     Xing Shui, Zheqi Wen, Dong, Ruimin, Chen, Zefeng, Tang, Leile, Wenyu Tang, Wu, Zhen, Chen, Lin · 2023 · Figshare